Incyte Corporation vs Riot Platforms Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Riot Platforms Inc trades at $16.89 (market cap $6.32B). The key difference: Incyte Corporation is far larger — about 3.6× Riot Platforms Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Riot Platforms Inc for 16 Days on average.
| INCY | RIOT | |
|---|---|---|
Market Cap | $22.85B | $6.32B |
Volume | 1,927,029 | 30,571,756 |
Sector | Health | Financials |
52-Week High | $129.93 | $28.67 |
52-Week Low | $83.80 | $11.83 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $18.35B | $6.73B |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
RIOT Platforms trades at $16.885, down 8.93% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported significant losses with a net income margin of -196.28% in 2026, though revenue grew to $675 million. Recent strategic shifts toward AI data center leasing, including a $9.1 billion contract, highlight transformation efforts amid challenging profitability.
While analyst consensus remains strongly bullish with a $31.64 price target, substantial execution risks and persistent negative earnings pose challenges. The stock's outlook hinges on successful monetization of AI infrastructure contracts and improved operational efficiency to stem cash flow deficits.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →